Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Director comp.
Quarterly results
TREVENA INC (TRVN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/14/2023 8-K Quarterly results
Docs: "TREVENA, INC. Condensed Statements of Operations Three Months Ended Jun 30, Six Months Ended Jun 30, 2023 2022 2023 2022 Product revenue $ 21 $ - $ 27 $ - License revenue 3,000 - 3,000 20 Total revenue 3,021 - 3,027 20 Operating expenses: Cost of goods sold 88 216 214 423 Selling, general and administrative 5,138 10,306 11,227 21,320 Research and development 3,991 4,291 7,900 9,550 Total operating expenses 9,217 14,813 19,341 31,293 Loss from operations Other income 483 Net loss $ $ $ $ Per share information: Net loss per share of common stock, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted 11,580,128 6,621,083 10,592,586 6,620,942 TREVENA, INC. Condensed Balance Sheets"
07/20/2023 8-K Quarterly results
05/15/2023 8-K Quarterly results
Docs: "TREVENA, INC. Condensed Statements of Operations Three Months Ended Mar 31, 2023 2022 Product revenue $ 6 $ - License revenue - 20 Total revenue 6 20 Operating expenses: Cost of goods sold 127 207 Selling, general and administrative 6,089 11,014 Research and development 3,909 5,259 Total operating expenses 10,125 16,480 Loss from operations Other income 2,300 71 Net loss $ $ Per share information: Net loss per share of common stock, basic and diluted $ $ Weighted average shares outstanding, basic and diluted 9,594,072 6,620,800 TREVENA, INC. Condensed Balance Sheets",
"CLIN PHASE 1 PHASE 2 PHASE 3 NDA POST"
05/09/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Trevena to Release First Quarter 2023 Financial Results on May 15, 2023"
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "About OLINVYK® injection OLINVYK is a new chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1 mL and 2 mg/2 mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia . Approved PCA doses are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information..."
04/21/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
03/13/2023 8-K Other Events  Interactive Data
01/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation Deck",
"TRV045 Overview Deck",
"Company Contact:"
11/29/2022 8-K Quarterly results
11/17/2022 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Other Events, Financial Sta...
Docs: "PRE-FUNDED COMMON STOCK PURCHASE WARRANT Trevena, Inc. Warrant Shares: _______ Issue Date:______, 2022 Initial Exercise Date: _______, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Trevena, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . In addition to the terms defined elsewhere in this Warr...",
"COMMON STOCK PURCHASE WARRANT Trevena, Inc. Warrant Shares: _______ Issue Date:______, 2022 Initial Exercise Date: _______, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on November 18, 2027 but not thereafter, to subscribe for and purchase from Trevena, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . In addition to the terms defined elsewhere in this Warrant, the followi...",
"Troutman Pepper Hamilton Sanders LLP",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of November 16, 2022, between Trevena, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree...",
"Investor Contact:"
11/09/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
09/12/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/11/2022 8-K Quarterly results
07/29/2022 8-K Quarterly results
07/28/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
04/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
04/20/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CLIN PHASE 1 PHASE 2 PHASE 3 NDA POST"
04/20/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "NEONATAL OPIOID WITHDRAWAL SYNDROME – Prolonged use of OLINVYK during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. RISK FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS – Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment option..."
03/31/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Investor Contact:"
01/27/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
12/23/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
10/04/2021 8-K Other Events  Interactive Data
09/07/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
08/04/2021 8-K Quarterly results
06/16/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy